Screener / SEC EDGAR /CIK 0001639691 /10-K filed Feb 25, 2026, compared with Feb 25, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Medical Devices

LivaNova PLC LIVN

Compare with peers Embed
The 10-K against last year's

164 changes: 23 added, 22 removed, 116 reworded, 3 quiet changes

10-K Feb 25, 2026 vs Feb 25, 2025

10-K 0001639691-26-000010 (Feb 25, 2026) vs 10-K 0001639691-25-000010 (Feb 25, 2025) Not compared: Legal Proceedings, Accounting Policies.

Every paragraph, and how much of it changed

One bar per paragraph, in the order of the 10-K. Height and colour show the share of its words not in the closest paragraph a year earlier; the tallest bars are new paragraphs.

Risk Factors

119 paragraphs · 14 new · 74 reworded · 12 gone · 10-K Feb 25, 2026 against Feb 25, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 103 · 48% changed Every version of it
Additionally, for each financial statement period after issuance of the 2025 Notes and 2029 Notes, a derivative gain or loss is and will be reported in LivaNova’s consolidated statements of income (loss) to the extent the valuations of the exchange feature and conversion feature, as applicable, change from the previous period. The 2025 Capped Calls and 2029 Capped Calls described below and elsewhere in this Report are also accounted for as derivative instruments. The valuation of the exchange feature of the 2025 Notes and 2025 Capped Calls utilizes significant observable and unobservable market inputs, including stock price, stock price volatility, risk-free interest rate, and time to expiration of the 2025 Notes. The valuation of the conversion feature of the 2029 Notes and 2029 Capped Calls similarly utilizes significant observable and unobservable market inputs, including stock price, expected volatility, risk-free interest rate, expected dividend yield, and time to expiration of the 2029 Notes. The change in input values at the current period-end compared to the previous period-end may result in a material change in the respective valuations and the gain or loss resulting from the exchange feature of the 2025 Notes and 2025 Capped Calls and the conversion feature of the 2029 Notes and 2029 Capped Calls, as applicable, and may not completely offset each other. As such, there may be a material net impact on LivaNova’s consolidated statements of income (loss), which could adversely affect the price at which its ordinary shares trade.
Paragraph 23 · 46% changed Every version of it
LivaNova operates in a highly competitive market characterized by increasingly complex products that are expensive and time- consuming to develop and manufacture. In the product lines in which LivaNova competes, the Company faces a mixture of competitors ranging from large manufacturers with multiple business lines to small manufacturers that offer a limited selection of specialized products. Development by other companies of new or improved products, processes, therapies, or technologies, including products developed with the effective use of advanced technologies like artificial intelligence, AI, may make LivaNova’s products or proposed products less competitive. The Company’s failure to adopt or integrate such advanced See “The incorporation and use of AI technologies may hinder product innovation, increase costs, present risks and impact challenges that could adversely affect LivaNova’s business, operations, and reputation.” below. Furthermore, if LivaNova fails to develop new and enhanced products and services on a timely basis, the Company’s offerings may become more expensive to maintain and eventually obsolete over time, and its competitiveness reputation, business, and operational efficiency. In addition, LivaNova faces competition from providers of alternative medical therapies, pharmaceuticals, and surgical interventions, among others. Competitive factors include product quality, reliability and performance; product technology and innovation; breadth of product lines and product services; ability to identify new market trends; changes to the regulatory environment; cost-effectiveness and financial results may be negatively impacted.
Paragraph 76 · 46% changed Every version of it
This will involve implementing processes to gather their own development, performance, and position in accordance with the relevant data, conduct materiality assessments, and prepare European Sustainability Reporting Standards. Preparing a CSRD-compliant report, which report will likely be a time-consuming and costly exercise, and in the event that LivaNova’s disclosures prove incorrect, the Company may incur liabilities. When producing will require a CSRD report, LivaNova may be required to obtain an limited assurance opinion with respect to the information in the report. from an outside audit firm. To the extent an adverse or qualified assurance conclusion opinion is reached delivered with respect to LivaNova’s report, the Company’s reputation may be impacted, and investors could lose confidence in the accuracy and completeness of its sustainability disclosures. Subject to the specific circumstances of an adverse or qualified conclusion, opinion, LivaNova may also be subject to sanctions set by EU Member States. Further, there are ongoing consultations that may result in further changes or amendments to CSRD. No final proposals have yet been set out, but this process could lead to significant changes to the CSRD regime. It is unclear as to how any such future changes could impact LivaNova.
Paragraph 25 · 44% changed Every version of it
Any The incorporation and use of the aforementioned AI technologies may present risks and challenges that could adversely affect LivaNova’s business, results of operations, cash flows, and financial condition. reputation.
Paragraph 75 · 43% changed Every version of it
There is a heightened focus on issues relating to sustainability, including environmental stewardship, social responsibility, and corporate governance matters. Increasing attention on sustainability issues related to LivaNova’s business requires continuous monitoring of various and evolving laws, regulations, standards, and expectations and the associated reporting requirements. For requirements, including public disclosure requirements from customers. It is unclear as to how any such future changes could impact LivaNova. In the event that LivaNova’s sustainability disclosures prove incorrect, the Company may incur regulatory consequences. The EU CSRD, for example, in 2023, the CSRD entered into force. Broadly, CSRD amends and strengthens the rules introduced on sustainability reporting for companies, banks and insurance companies under the NFRD and will require a much broader range of in-scope companies to publicly report public reporting on their covered companies’ impact on sustainability matters as well as how sustainability matters affect their own development, performance and position in accordance with the ESRS. To the extent LivaNova is in scope of the reporting requirements under CSRD, the Company will be required to provide such information with its management report.
Paragraph 38 · 36% changed Every version of it
Failure to comply with U.S. and international product-related government regulations may materially adversely affect regulatory requirements could have a material adverse effect on LivaNova’s business, results of operations, cash flows, and financial condition.
Paragraph 16 · 34% changed Every version of it
Unauthorized disclosure or use of, denial of access to, or other incidents involving sensitive or confidential customer, patient, employee, vendor or Company data, whether through systems failure, employee negligence, fraud, misappropriation, cybersecurity incidents, or other intentional or unintentional acts, could expose and have exposed the Company to liability under various laws and regulations across jurisdictions and increase the risk of litigation and governmental or regulatory investigation, damage LivaNova’s reputation and its competitive positioning in the marketplace, disrupt its or its customers’ business operations, or cause LivaNova to lose customers, potentially resulting in significant financial exposure and legal liability. Similarly, unauthorized access to or through, denial of access to, or other incidents involving LivaNova or its vendors’ information IT systems, whether by the Company’s employees or third parties, including a cyber-attack by criminal hackers, or state-sponsored organizations, who continuously develop and deploy viruses, ransomware, malware, or other malicious software programs or social engineering attacks, have resulted and could in the future result in negative publicity, significant remediation costs, legal liability, notification requirements, and damage to LivaNova’s reputation, which could have a material adverse effect on the Company’s business, results of operations, cash flows, and financial condition.
Paragraph 30 · 32% changed Every version of it
As a result of acquisitions, LivaNova may face risks due to arising from the implementation, modification, or remediation of controls, procedures, and policies relating related to data privacy and cybersecurity at the acquired company. In addition, failure Failure to manage and coordinate the growth of the combined company successfully could have an adverse impact on LivaNova’s business. Similarly, LivaNova may divest and has divested portions of its business, resulting in the migration of data and overlapping data obligations. As a result of such divestitures, LivaNova may face risks due to the migration or modification of controls, procedures, and policies relating to data privacy and cybersecurity internally or en route during migration. Any significant breakdown, intrusion, interruption, corruption, or destruction of these systems, as well as any data breaches, could have a material adverse effect on LivaNova’s business.

MD&A

77 paragraphs · 9 new · 40 reworded · 10 gone · 10-K Feb 25, 2026 against Feb 25, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 74 · 49% changed
If LivaNova is subject to interest rates rate risk on its variable-rate depository accounts and financing arrangement, the Term Facilities. Interest expense associated with LivaNova’s variable-rate financing arrangements as the Term Facilities is principally offset by holding proceeds from the Term Facilities in a depository account, which earns a floating rate of interest. As of December 31, 2024 were to increase/(decrease) by 2025, a 100 basis points, point increase/(decrease) in the effect interest rates of LivaNova’s variable-rate depository accounts would increase/(decrease) interest income on interest expense within LivaNova’s the Company’s consolidated statements of income (loss) by $5.6 million. As of December 31, 2025, a 100 basis point change in the interest rate of the Term Facilities would be an increase/(decrease) not have a material effect on LivaNova’s consolidated results of $3.2 million, respectively, offset by an increase/(decrease) operations, cash flows, or financial position. For additional information, refer to “Note 9. Financing Arrangements” in interest income from amounts held the consolidated financial statements in variable-rate depository accounts. this Report.
Paragraph 18 · 46% changed
LivaNova has adopted various accounting policies to prepare the consolidated (1)The above table presents revised financial statements in accordance with U.S. GAAP. The Company’s most significant accounting policies are disclosed results, as discussed in “Note 2. Basis of Presentation, Use of Accounting Estimates, and Significant Accounting Policies” and “Note 3. Revenue Recognition” 20. Revision of Previously Issued Financial Statements” in LivaNova’s the consolidated financial statements included in this Report.
Paragraph 9 · 46% changed
Through December 31, 2024, LivaNova incurred direct costs totaling $11.6 million in connection with this cybersecurity incident, including $9.0 million and $2.6 million during the twelve months ended December 31, 2024 and 2023, respectively. The total incurred direct costs primarily included external cybersecurity expert and legal fees, system restoration costs, and a $1.2 million provision related to the class action settlement, and do not include business interruption losses. The Company expects to incur additional costs related to this incident in the future. For further discussion on legal and regulatory developments, refer to “Note 11. Commitments and Contingencies” in LivaNova’s consolidated financial statements in this Report. LivaNova maintains insurance, including cyber insurance, which is subject to certain retentions and policy limitations that will likely limit the amount that the insurers may reimburse the Company. LivaNova has filed claims for insurance reimbursement of covered direct costs and business interruption losses related to this incident and and, as of December 31, 2025, the reimbursement process is substantially complete. Through December 31, 2025, LivaNova has submitted additional claims and supplemental requests for reimbursement as new costs have been incurred. During 2024, LivaNova received $8.4 million, $10.7 million of insurance reimbursements, including $5.1 $6.8 million in reimbursement of covered direct costs and $3.3 $3.9 million in reimbursement of business interruption losses under losses. For the Company’s cyber insurance policy. The Company’s insurance coverage may be insufficient to cover all years ended December 31, 2025 and 2024, LivaNova received $1.7 million and $5.1 million, respectively, in reimbursement of direct costs. For the years ended December 31, 2025 and 2024, LivaNova received $0.6 million and $3.3 million, respectively, in reimbursement of business interruption losses. LivaNova will submit additional claims for reimbursement if incremental costs and expenses related to this cybersecurity incident or may be unavailable to cover all costs and expenses related to this cybersecurity incident.
Paragraph 11 · 43% changed
LivaNova identifies operating segments based on how it manages, evaluates, and internally reports its business activities to allocate resources, develop, and execute its strategy and assess performance. Prior to 2024, LivaNova operated through three segments: Cardiopulmonary, Neuromodulation, and ACS. During the first quarter of 2024, the Company reorganized its operating and reporting structure upon initiating the 2024 Restructuring Plan. This involved transitioning all ACS standalone cannulae and accessories, including ProtekDuo and transseptal (TandemHeart) cannulae, into its Cardiopulmonary segment. Operations for other ACS products, including LifeSPARC and Hemolung systems, were discontinued in 2024. For additional information, refer to “Note 4. Restructuring” in LivaNova’s consolidated financial statements in this Report. This restructuring, along with changes in how the Company’s CODM regularly reviews information, allocates resources, and assesses performance, resulted in modifications to LivaNova’s reportable segments. Specifically, LivaNova’s former ACS segment is now included in “Other,” excluding the ACS standalone cannulae and accessories business, which is now included in the Cardiopulmonary reportable segment. As a result, LivaNova now has two reportable segments: Cardiopulmonary and Neuromodulation. The segment financial information presented herein reflects these changes for all periods presented. For additional information regarding LivaNova’s reportable segments, historical financial information, and its methodology for the presentation of financial results, refer to the consolidated financial statements and accompanying notes of this Report.
Paragraph 8 · 40% changed
Through December 31, 2024, 2025, LivaNova incurred direct costs totaling $11.6 $13.1 million in connection with this cybersecurity incident, including $1.5 million, $9.0 million and $2.6 million during for the twelve months years ended December 31, 2024 2025, 2024, and 2023, respectively. The total incurred direct costs incurred primarily included include external cybersecurity expert and legal fees, system restoration costs, and a $1.2 million provision related to the a class action settlement, and do not include business interruption losses. The Company expects to may incur additional costs related to this incident in the future. For further discussion on legal and regulatory developments, refer to “Note 11. Commitments and Contingencies” in LivaNova’s consolidated financial statements in this Report. LivaNova maintains insurance, including cyber insurance, which is subject to certain retentions and policy limitations that will likely limit the amount that the insurers may reimburse the Company. LivaNova has filed claims for insurance reimbursement of covered costs and business interruption losses related to this incident and has submitted additional claims and supplemental requests for reimbursement as new costs have been incurred. During 2024, LivaNova received $8.4 million, including $5.1 million in reimbursement of covered costs and $3.3 million in reimbursement of business interruption losses under the Company’s cyber insurance policy. The Company’s insurance coverage may be insufficient to cover all costs and expenses related to this cybersecurity incident or may be unavailable to cover all costs and expenses related to this cybersecurity incident.
Paragraph 71 · 40% changed
Cash provided by used in financing activities during for the year ended December 31, 2024 decreased $2.9 2025 increased $304.2 million, compared to the prior year, primarily due to payment resulting from repayments of long-term debt obligations in 2025, including an early repayment of $200 million on principal borrowings under the Term Facilities and the repayment in full of the ALung contingent consideration arrangement 2025 Notes at maturity of $13.8 million during the year ended December 31, 2024, partially offset by an increase in proceeds from net debt borrowings and repayments of $5.7 $57.5 million.
Paragraph 43 · 40% changed
LivaNova’s effective income tax rate was (9.8%) and 28.4% and 121.7% for the years ended December 31, 2024 2025 and 2023, 2024, respectively. Compared with the year ended December 31, 2023, 2024, the change in the effective tax rate for 2024 2025 was primarily attributable to year-over-year changes in income before income tax in countries with varying statutory tax rates, certain discrete tax items, including the mix of taxable income in various jurisdictions, non-deductible interest and premiums, SNIA environmental liability, and changes in tax valuation allowances. For additional information, please refer to “Note 15. Income Taxes” in LivaNova’s consolidated financial statements included in this Report.
Paragraph 33 · 37% changed
R&D expenses as a percentage of net revenue were 14.6% 13.4% for the year ended December 31, 2024, 2025, representing a decrease of 2.2 1.2 percentage points compared to the year ended December 31, 2023. 2024. The decrease was primarily due to a decline reductions in R&D expense of $24.8 million costs associated with winding down the Company’s heart failure program, which was completed during the fourth quarter DTD program of 2023, as well as a decline of $6.3 $18.9 million, partially offset by an $11.2 million increase in costs associated with winding down the Company’s ACS segment, as described above. development of LivaNova’s aura6000 System for treating OSA.

A paragraph is matched with the one last year that shares the most of its words; under half in common makes it new. The paragraphs shown are the 8 reworded the most in each section.

The paragraph that changed most in each section

The redline

Marked against last year's 10-K: cut words struck through, new words highlighted.

MD&A166 words changed in this paragraph; it is 46% similar to last year's version.
Through December 31, 2024, 2025, LivaNova incurred direct costs totaling $11.6 $13.1 million in connection with this cybersecurity incident, including $1.5 million, $9.0 million and $2.6 million during for the twelve months years ended December 31, 2024 2025, 2024, and 2023, respectively. The total incurred direct costs incurred primarily included include external cybersecurity expert and legal fees, system restoration costs, and a $1.2 million provision related to the a class action settlement, and do not include business interruption losses. The Company expects to may incur additional costs related to this incident in the future. For further discussion on legal and regulatory developments, refer to “Note 11. Commitments and Contingencies” in LivaNova’s consolidated financial statements in this Report. LivaNova maintains insurance, including cyber insurance, which is subject to certain retentions and policy limitations that will likely limit the amount that the insurers may reimburse the Company. LivaNova has filed claims for insurance reimbursement of covered costs and business interruption losses related to this incident and has submitted additional claims and supplemental requests for reimbursement as new costs have been incurred. During 2024, LivaNova received $8.4 million, including $5.1 million in reimbursement of covered costs and $3.3 million in reimbursement of business interruption losses under the Company’s cyber insurance policy. The Company’s insurance coverage may be insufficient to cover all costs and expenses related to this cybersecurity incident or may be unavailable to cover all costs and expenses related to this cybersecurity incident.

Source: Item 7, 10-K 0001639691-26-000010 vs Item 7, 10-K 0001639691-25-000010

Risk Factors161 words changed in this paragraph; it is 44% similar to last year's version.
LivaNova operates in a highly competitive market characterized by increasingly complex products that are expensive and time- consuming to develop and manufacture. In the product lines in which LivaNova competes, the Company faces a mixture of competitors ranging from large manufacturers with multiple business lines to small manufacturers that offer a limited selection of specialized products. Development by other companies of new or improved products, processes, therapies, or technologies, including products developed with the effective use of advanced technologies like artificial intelligence, AI, may make LivaNova’s products or proposed products less competitive. The Company’s failure to adopt or integrate such advanced See “The incorporation and use of AI technologies may hinder product innovation, increase costs, present risks and impact challenges that could adversely affect LivaNova’s business, operations, and reputation.” below. Furthermore, if LivaNova fails to develop new and enhanced products and services on a timely basis, the Company’s offerings may become more expensive to maintain and eventually obsolete over time, and its competitiveness reputation, business, and operational efficiency. In addition, LivaNova faces competition from providers of alternative medical therapies, pharmaceuticals, and surgical interventions, among others. Competitive factors include product quality, reliability and performance; product technology and innovation; breadth of product lines and product services; ability to identify new market trends; changes to the regulatory environment; cost-effectiveness and financial results may be negatively impacted.

Source: Item 1A, 10-K 0001639691-26-000010 vs Item 1A, 10-K 0001639691-25-000010

Sentences and paragraphs added, removed or reworded

Every change, by type

Sentences and paragraphs of LIVN's Risk Factors and MD&A, 10-K Feb 25, 2026 against 10-K Feb 25, 2025. Each links to the text at sec.gov.

Quiet changes are sentences kept from last year with one to four words changed, at least one of them a hedge, a modal or a qualifier (may, could, will, not, significant, material…). A year or date rolling forward is not counted.

The full word list

adverse, adversely, all, although, anticipate, anticipates, any, approximately, believe, believes, can, cannot, certain, could, expect, expects, generally, however, if, intend, intends, largely, likely, many, material, materially, may, might, most, must, never, no, not, possible, primarily, probable, should, significant, significantly, some, substantial, substantially, unlikely, will, would

AddedRisk Factors
Changes in global trade policies, including the imposition of tariffs, trade restrictions, export controls, sanctions, or other protectionist or retaliatory measures by the U.S. or other jurisdictions, may adversely affect LivaNova’s business, financial condition, and results of operations.
Read it in 10-K Feb 25, 2026 at sec.gov
AddedRisk Factors
Global trade conditions have become increasingly dynamic and subject to rapid change. A significant number of LivaNova’s Cardiopulmonary products and component parts are sourced and produced outside of the U.S., including in Italy and Germany. Similarly, LivaNova manufactures its Neuromodulation products in the U.S., which are then often distributed internationally. Governments in the jurisdictions in which the Company operates, sources materials, manufactures products, or sells into markets may impose new or increased tariffs, duties, quotas, export or import restrictions, sanctions, or other trade measures. In addition, a recent U.S. Supreme Court ruling affecting tariff administration and the potential for refund processes may create further uncertainty, including potential delays, backlogs, or unpredictability in the timing or availability of tariff refunds. Any of the aforementioned actions, including reciprocal or retaliatory measures by affected countries, could increase LivaNova’s costs of raw materials, components, and finished goods; disrupt the company’s supply chain; limit market access; or otherwise negatively affect global operations.
Read it in 10-K Feb 25, 2026 at sec.gov
AddedRisk Factors
Increases in input or product costs resulting from trade measures may require LivaNova to raise prices, reduce margins, modify sourcing strategies, or absorb additional costs. Any price increases, to the extent implemented, could reduce demand for the company’s products, adversely affect competitiveness in domestic and international markets, and negatively impact revenues, profitability, and overall results of operations.
Read it in 10-K Feb 25, 2026 at sec.gov
AddedRisk Factors
Failure to protect, maintain, or upgrade LivaNova’s IT systems or products, or safeguard against cybersecurity incidents, service disruptions, or data corruption could have a material adverse effect on LivaNova’s business, results of operations, financial condition and reputation.
Read it in 10-K Feb 25, 2026 at sec.gov
AddedRisk Factors
LivaNova operates in a highly competitive market characterized by increasingly complex products that are expensive and time-consuming to develop and manufacture. The Company’s success depends on several factors, including its ability to appropriately allocate the Company’s R&D resources, integrate advanced software and AI capabilities, attract and retain key talent, achieve market adoption of its technologies, and sustain innovation. In the product lines in which LivaNova competes,
Read it in 10-K Feb 25, 2026 at sec.gov
AddedRisk Factors
AI technologies are increasingly being used across the global business landscape, including in the development of new or improved products and therapies in the medical technology industry. LivaNova has already employed certain AI technologies in its business in an attempt to enhance the Company’s products, technology, and therapies and reduce development time and cost. The Company may not be able to successfully integrate AI technologies into its operations or ensure usage of AI will be beneficial to LivaNova’s business, including the Company’s efficiency or profitability. Flaws, breaches, or malfunctions in these systems could lead to disruptions, data loss, or erroneous decision-making, impacting LivaNova’s business operations, financial condition, and reputation. Legal challenges may arise, including, or as a result of, cybersecurity incidents, non-compliance with data protection regulations, and a lack of transparency relating to the use of AI. The regulatory landscape and industry standards surrounding AI technologies are also rapidly evolving and remain uncertain. As governments and regulatory bodies around the world continue to develop and implement new laws and standards governing AI, compliance with these evolving requirements may require significant additional resources and expenditures. Such regulations could also restrict or delay LivaNova’s ability to effectively develop, deploy, or utilize AI technologies, which could adversely affect the Company’s competitiveness and operational efficiency. If LivaNova fails to keep pace with the rapid evolution of AI technologies, the Company’s competitive position and business results could suffer.
Read it in 10-K Feb 25, 2026 at sec.gov
AddedRisk Factors
In addition, if LivaNova’s investments, alliances, acquisitions, or divestitures are not successful, the Company may incur costs in excess of what it anticipates, including, but not limited to, losses arising from related litigation, reputational damage, or other unforeseen liabilities. Furthermore, in the event of any acquisition, whether successful or not, LivaNova may be exposed to
Read it in 10-K Feb 25, 2026 at sec.gov
AddedRisk Factors
LivaNova’s products and manufacturing operations are subject to extensive regulation by the FDA and by regulatory authorities outside the U.S., including under the MDR. The Company must comply with numerous requirements throughout the product lifecycle, including design controls, manufacturing practices, labeling, adverse event reporting, and promotional restrictions.
Read it in 10-K Feb 25, 2026 at sec.gov
Show the other 62
AddedRisk Factors
LivaNova’s facilities and those of its suppliers are subject to periodic inspections and audits. These inspections have resulted in Form 483 observations and other findings in the past, and future inspections may result in additional observations, warning letters, or other enforcement actions. If regulators determine that the Company is not in compliance, they may take actions that include restricting manufacturing operations; delaying, refusing, or withdrawing product approvals or clearances; requiring product recalls, repairs, or replacements; seizing or detaining products; imposing civil or criminal penalties; or recommending prosecution. These actions could disrupt the Company’s operations, limit its ability to market existing or future products, and require significant expenditures to address compliance issues.
Read it in 10-K Feb 25, 2026 at sec.gov
AddedRisk Factors
The Company is also subject to strict limitations on product promotion. Although healthcare professionals may use devices for off‑label indications, LivaNova is prohibited from promoting products for uses not included in the approved labeling. Any failure to comply with these promotional restrictions could result in substantial civil or criminal liability, additional compliance obligations, and reputational harm.
Read it in 10-K Feb 25, 2026 at sec.gov
AddedRisk Factors
Shareholder activism and increased investor engagement could divert management’s attention, disrupt the Company’s operations, and adversely affect the business and share price.
Read it in 10-K Feb 25, 2026 at sec.gov
AddedRisk Factors
Shareholder activism and heightened investor engagement have become more prevalent across public companies. LivaNova may be, and in certain instances, has been, subject to shareholder proposals, proxy contests, public campaigns, or other actions by activist investors or other shareholders seeking to influence its governance, strategic direction, capital allocation, operational decisions, or executive compensation practices.
Read it in 10-K Feb 25, 2026 at sec.gov
RemovedRisk Factors
Conflicts, for example, including those in Ukraine and the Middle East, have caused the Company to assess its ability to source materials, manage transportation costs, sell product, collect payment, and comply with international sanctions. These conflicts have increased economic and regulatory uncertainties, and a significant escalation or continuation of these conflicts could have a material impact on the Company’s operating results.
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedRisk Factors
Cybersecurity incidents or other disruptions to LivaNova’s information technology systems could lead to reduced revenue, increased costs, liability claims, regulatory fines, litigation, harm to LivaNova’s competitive position, and loss of reputation.
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedRisk Factors
As previously disclosed, in November 2023, LivaNova detected a cybersecurity incident that resulted in a disruption of portions of the Company’s information technology systems. Promptly after detecting the issue, LivaNova began an investigation with assistance from external cybersecurity experts and coordinated with law enforcement. The Company implemented remediation measures to mitigate the impact of the incident. The Company also assessed the nature and scope of the affected data, analyzed its statutory notification obligations, and notified affected individuals and regulators as required by applicable law. The incident has been contained, and the Company’s mitigation efforts are considered complete, but any future cybersecurity event has the potential to materially affect its results of operations, cash flows, and financial condition.
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedRisk Factors
LivaNova’s research and development efforts rely upon investments and investment collaborations, and the Company cannot guarantee that any previous or future investments or investment collaborations will be successful.
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedRisk Factors
The rapid pace of technological development in the medical industry and the specialized expertise required in different areas of medicine make it difficult for one company alone to develop a broad portfolio of technological solutions. As a result, LivaNova also relies on investments and investment collaborations to provide the Company access to new technologies. If LivaNova fails to develop new and enhanced products and services on a timely basis, the Company’s offerings may become more expensive to maintain and eventually obsolete over time, and its reputation, business, and financial results may be negatively impacted. LivaNova’s success depends on several factors, including its ability to appropriately allocate the Company’s R&D funding to products and services with higher growth prospects, for example, further incorporation of software, hiring and retaining the necessary R&D talent, stimulating customer demand for and convincing customers to adopt new technologies, innovating and developing new technologies and applications, and acquiring or obtaining third-party technologies that may have valuable applications in the markets that LivaNova serves.
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedRisk Factors
Both before and after a product is commercially released, LivaNova has ongoing responsibilities under FDA and other applicable non-U.S. government agency regulations. For instance, many of LivaNova’s facilities and procedures and those of its suppliers are subject to periodic inspections by the FDA, which can result, and in the past has resulted, in inspection observations on the FDA’s Form 483, warning letters, or other forms of enforcement. If the FDA were to conclude that LivaNova is not in compliance with applicable laws or regulations, or that any of the Company’s medical products are ineffective or pose an unreasonable health risk, the FDA could ban such medical products; detain or seize adulterated or misbranded medical products; order a recall, repair, replacement, or refund of such products; refuse to grant pending PMA applications; and/or require LivaNova to notify health professionals and others that the devices present an unreasonable risk of substantial harm to the public health. Similar consequences could follow, such as audits by non-U.S. regulators and notified bodies.
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedRisk Factors
The FDA and other non-U.S. government agencies could also assess civil or criminal penalties against LivaNova, the Company’s officers, or other employees and/or impose operating restrictions on a company-wide basis. The FDA could also recommend prosecution to the U.S. Department of Justice. An adverse regulatory action could restrict LivaNova from effectively marketing and selling its products, limit its ability to obtain future pre-market clearances or PMAs, and result in a substantial modification to LivaNova’s business practices and operations. These potential consequences, as well as any adverse outcome from government investigations, could have a material adverse effect on LivaNova’s business, results of operations, cash flows, and financial condition.
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedRisk Factors
In addition, device manufacturers are prohibited from promoting their products for uses and indications that are not consistent with the approved product labeling (so called “off-label uses”). While physicians may exercise their discretion in prescribing a device for an off-label use, a device manufacturer’s failure to comply with the related applicable regulations could subject LivaNova to significant civil or criminal exposure, administrative obligations and costs, and/or other potential penalties.
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedRisk Factors
Governmental regulations outside the U.S. have, and may continue to, become increasingly stringent and common as well. For example, MDR has resulted in significant additional pre-market and post-market requirements. Certifications to MDR must be achieved by December 2027 or December 2028, based on the risk classification of the device. In the interim, the European Commission is allowing companies to use their MDD certifications. LivaNova is working to obtain all appropriate approvals as required, as penalties for regulatory non-compliance can be severe, including fines and revocation or suspension of a
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedRisk Factors
Company’s technology, and may limit LivaNova’s competitive advantage. Third parties could obtain patents that may require LivaNova to negotiate licenses to conduct business, and the required licenses may not be available on reasonable terms or at all.
Read it in 10-K Feb 25, 2025 at sec.gov
RewordedRisk Factors
Broadly, CSRD The EU CSRD, for example, amends and strengthens the rules introduced on sustainability reporting for companies, banks and insurance companies under the NFRD and will require a much broader range of in-scope companies to publicly report public reporting on their covered companies’ impact on sustainability matters as well as how sustainability matters affect their own development, performance and position in accordance with the ESRS.
Read it in 10-K Feb 25, 2026 at sec.gov
RewordedRisk Factors
The 2025 Capped Calls and 2029 Capped Calls are expected generally to compensate (through the payment of cash to LivaNova) for potential dilution to LivaNova’s ordinary shares and to offset cash payments due upon exchange of the 2025 Notes or conversion of the 2029 Notes, as applicable, Notes in excess of the principal amount thereof in the event that the market price per ordinary share of LivaNova at the time of exchange of the 2025 Notes or conversion of the 2029 Notes, respectively, Notes is greater than the strike price under the 2025 2029 Capped Calls or 2029 Capped Calls, respectively, with such offset subject to a cap based on the respective cap prices of the 2025 Capped Calls and 2029 Capped Calls.
Read it in 10-K Feb 25, 2026 at sec.gov
RewordedRisk Factors
The Option Counterparties or their respective affiliates may modify these initial hedge positions by entering into or unwinding various transactions with respect to LivaNova’s ordinary shares and/or purchasing or selling its ordinary shares or other of LivaNova’s securities in secondary market transactions prior to the maturity of the 2025 2029 Notes and/or 2029 Notes, as applicable (and are likely to do so during any observation period related to an exchange of the 2025 Notes or a conversion of the 2029 Notes, as applicable, Notes or upon a repurchase or redemption of the 2025 2029 Notes or the 2029 Notes, as applicable, by LivaNova, if LivaNova unwinds a corresponding portion of the 2025 Capped Calls or 2029 Capped Calls, as applicable). Calls).
Read it in 10-K Feb 25, 2026 at sec.gov
RewordedRisk Factors
The effective interest rate and related interest expense reported in LivaNova’s consolidated financial statement of operations the 2029 Notes is significantly greater than the stated interest rate of the 2025 Notes and 2029 Notes and rate, which may result in volatility to the Company’s reported interest expense and financial results, which results and could adversely affect the price at which LivaNova’s ordinary shares trade.
Read it in 10-K Feb 25, 2026 at sec.gov
RewordedRisk Factors
The success of any investment investment, alliance, acquisition, or divestiture may be affected by a number of several factors, including the Company’s ability to identify and then properly assess and value the potential business opportunity. opportunity and obtain relevant approvals for a potential business opportunity or to successfully integrate any business LivaNova may acquire.
Read it in 10-K Feb 25, 2026 at sec.gov
RewordedRisk Factors
For example, holders are entitled to exchange 2025 Notes or convert 2029 Notes during a given calendar quarter if the closing price of LivaNova’s ordinary shares for at least 20 trading days (whether or not consecutive) during the last 30 consecutive trading days of the immediately preceding calendar quarter was greater than or equal to a set dollar amount ($79.27 per share in the case of the 2025 Notes and $90.22 in the case of the 2029 Notes, $90.22, subject to adjustment). adjustment.
Read it in 10-K Feb 25, 2026 at sec.gov
RewordedRisk Factors
If holders exchange 2025 Notes during any future period in which such exchange is permitted, LivaNova would be required to settle its exchange obligation through the payment of cash, and if holders convert 2029 Notes during any future period in which such conversion is permitted, LivaNova would be required to pay cash up to the aggregate principal amount of the 2029 Notes to be converted and may elect to settle the remainder of the conversion obligation in cash, shares, or a combination of the two.
Read it in 10-K Feb 25, 2026 at sec.gov
RewordedRisk Factors
The change in input values at the current period-end compared to the previous period-end may result in a material change in the respective valuations valuation and the gain or loss resulting from the exchange feature of the 2025 Notes and 2025 Capped Calls and the conversion feature of the 2029 Notes and 2029 Capped Calls, as applicable, and may not completely offset each other.
Read it in 10-K Feb 25, 2026 at sec.gov
RewordedRisk Factors
If the conditional exchange feature of the 2025 Notes is triggered, holders are entitled to exchange the 2025 Notes at any time during specified periods, at their option, and if the conditional conversion feature of the 2029 Notes is triggered, holders are entitled to convert the 2029 Notes at any time during specified periods, at their option.
Read it in 10-K Feb 25, 2026 at sec.gov
RewordedRisk Factors
The Company has experienced and is continually at risk of being subject to cybersecurity incidents and other disruptions. disruptions, as exemplified by the previously disclosed November 2023 cybersecurity incident that resulted in the disruption of portions of the Company’s IT systems.
Read it in 10-K Feb 25, 2026 at sec.gov
RewordedRisk Factors
These risks, many of which LivaNova has experienced first-hand, include higher danger of terrorist activity, war, or civil unrest; greater exposure to inflation; volatility in freight and labor costs; fluctuating interest and exchange rates; increased exposure to cyber-attacks and supply chain challenges; changes to trade protection measures such as agreements and relationships between countries, including the uncertainty of global tariffs, trade restrictions, evolving sanctions, and adverse changes in import and export licensing requirements; changing energy prices; local product changes and compliance requirements; longer payment terms and collection times for receivables in local jurisdictions; difficulty enforcing agreements; greater exposure to creditworthiness of customers and inconsistent local law enforcement of obligations; ensuring compliance with anti-bribery laws; differing labor regulations and workforce instability; selling by way of distributors and agents; and political and economic instability.
Read it in 10-K Feb 25, 2026 at sec.gov
RewordedRisk Factors
LivaNova may not have sufficient cash flow from its business operations to pay when due, or be able to raise the funds necessary to pay when due, amounts owed with respect to the 2025 Notes and 2029 Notes and/or any amounts owed under the Company’s revolving credit facility and term facilities, LivaNova’s indebtedness, which could adversely affect LivaNova’s business and results of operations.
Read it in 10-K Feb 25, 2026 at sec.gov
Quiet changesRisk Factors
If LivaNova’s marketed medical devices are defective or otherwise pose safety risks, the FDA and similar non-U.S. governmental authorities could require their recall or initiate an enforcement action, or LivaNova may could initiate a recall of the Company’s products or stop sales of products voluntarily.
Read it in 10-K Feb 25, 2026 at sec.gov
Quiet changesRisk Factors
Changes in tax laws or exposure to additional income tax liabilities could have a material impact adverse effect on LivaNova’s results of operations and financial condition.
Read it in 10-K Feb 25, 2026 at sec.gov
AddedMD&A
In addition, the impact that the imposition of tariffs and changes to global trade policies could have on the Company’s results of operations is uncertain. A significant number of LivaNova’s Cardiopulmonary products and component parts are sourced and produced outside of the U.S., including in Italy and Germany. Similarly, LivaNova manufactures its Neuromodulation products in the U.S., which are then often distributed internationally. For additional information, refer to “Item 1A. Risk Factors” in this Report.
Read it in 10-K Feb 25, 2026 at sec.gov
AddedMD&A
are incurred. The Company’s insurance coverage may be insufficient to cover all costs and expenses related to this cybersecurity incident or may be unavailable to cover all costs and expenses related to this cybersecurity incident.
Read it in 10-K Feb 25, 2026 at sec.gov
AddedMD&A
CPB is frequently utilized in various heart-related medical procedures and allows surgical teams to oxygenate and circulate a patient’s blood, providing the necessary conditions for the surgeon to operate on the heart. Medical procedures most commonly requiring CPB include traditional coronary artery bypass grafting and valve surgeries. LivaNova’s products enable CPB for neonatal, pediatric, and adult patients.
Read it in 10-K Feb 25, 2026 at sec.gov
AddedMD&A
On March 14, 2025, the Italian Supreme Court issued its decision in response to all of the appeals of the Company and counter-appeals submitted by the Public Administrations. The Italian Supreme Court determined that LivaNova can be held jointly and severally liable for the established liabilities of SNIA at the time of demerger, as well as the environmental liabilities of the demerged company that materialized after the demerger, which are derived from actions performed prior to the demerger. As a result of the decision by the Italian Supreme Court, the Company recorded the SNIA environmental liability expense for the year ended December 31, 2025. For additional information, refer to “Note 11. Commitments and Contingencies” in the consolidated financial statements in this Report.
Read it in 10-K Feb 25, 2026 at sec.gov
AddedMD&A
determining whether a valuation allowance is required. Depending on operating results in the future, a release of the valuation allowance could occur within the next 12 months. The timing and amount of the valuation allowance release could vary based on the Company’s assessment of all available evidence.
Read it in 10-K Feb 25, 2026 at sec.gov
AddedMD&A
On July 4, 2025, the U.S. enacted the OBBBA. LivaNova has accounted for the relevant changes effective for tax year 2025 within its annual effective tax rate. Additionally, LivaNova is subject to income taxes as well as non-income-based taxes in the U.S., the UK, the EU, and various other jurisdictions. The OECD released guidance on January 5, 2026 to further modify Pillar Two rules including changes to substance-based non-refundable tax credits. LivaNova will continue to monitor legislative developments by the OECD, the UK, the EU, the U.S., and other jurisdictions worldwide that may impact LivaNova’s operations regarding Pillar Two and the OBBBA. For additional information, refer to “Note 15. Income Taxes” in LivaNova’s consolidated financial statements included in this Report.
Read it in 10-K Feb 25, 2026 at sec.gov
AddedMD&A
2025 2024 2023 Operating activities $ 254,340 $ 183,038 $ 74,914 Investing activities (72,912) (48,160) (40,331) Financing activities (285,660) 18,551 21,484 Effect of exchange rate changes on cash, cash equivalents, and restricted cash 16,228 (7,745) 6,187 Net (decrease) increase in cash, cash equivalents, and restricted cash $ (88,004) $ 145,684 $ 62,254
Read it in 10-K Feb 25, 2026 at sec.gov
AddedMD&A
Due to the global nature of LivaNova’s operations, the Company is exposed to FX fluctuations. LivaNova uses freestanding derivative forward contracts to offset exposure to the variability of the value associated with intercompany loans denominated in a foreign currency. As of December 31, 2025, a 100 basis point change in the exchange rate of the U.S. dollar against the prevailing market rates of foreign currencies involving balance sheet transactional exposures would not have a material effect on LivaNova’s consolidated results of operations, cash flows, or financial position. For additional information, refer to “Note 2. Basis of Presentation, Use of Accounting Estimates, and Significant Accounting Policies” and “Note 7. Derivatives and Risk Management” in the consolidated financial statements in this Report.
Read it in 10-K Feb 25, 2026 at sec.gov
RemovedMD&A
LivaNova continues to make investments in R&D focused on improving the VNS Therapy System with an enhanced pulse generator, lead, and programming software, and LivaNova is developing new products that provide additional features and functionality. LivaNova also supports studies for the Company’s product development efforts and to build clinical evidence for the VNS Therapy System.
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedMD&A
Peer reviewed evidence published in 2021 and 2022 continues to confirm the safety, efficacy, and cost effectiveness of VNS Therapy in both the adult and pediatric patient populations. In January 2022, the Journal of Neurology published a meta-analysis and systematic review that demonstrated the benefits of VNS Therapy in adults with DRE and improvements in seizure frequency without an increase in the rate of serious adverse events or discontinuations for that population. These data further support consideration of VNS Therapy for people who are not responding to ASMs and those unsuitable or unwilling to undergo surgery.
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedMD&A
2024 2023 2022 Cost of sales 30.5% 33.1% 30.8% Selling, general, and administrative 42.0% 44.9% 45.9% Research and development 14.6% 16.8% 15.2% Impairment of goodwill —% —% 12.7% Impairment of long-lived assets —% 7.8% —% Other operating expenses 2.6% 3.3% 2.9%
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedMD&A
LivaNova tests goodwill and indefinite-lived intangible assets for impairment on an annual basis on October 1, or when events or changes in circumstances indicate that a potential impairment exists.
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedMD&A
On January 5, 2024, the Board of Directors of LivaNova PLC approved the 2024 Restructuring Plan to enhance the Company’s focus on its core Cardiopulmonary and Neuromodulation segments. The main component of the 2024 Restructuring Plan was to wind down the ACS segment, which was substantially completed in 2024. The Company determined that it was more likely than not that the carrying amounts associated with the ACS segment, including the long-lived assets (asset group), may not be recoverable. This was determined to be a triggering event occurring in the fourth quarter of 2023 requiring an impairment assessment, based on certain factors, including the results of an updated long-term financial outlook for the ACS segment. As such, LivaNova recorded impairments of the following long-lived assets during the year ended December 31, 2023 (in thousands):
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedMD&A
On March 8, 2024, LivaNova issued $345.0 million aggregate principal amount of 2.50% notes due 2029. The 2029 Notes are senior unsecured obligations of the Company. In connection with pricing the 2029 Notes, the Company entered into privately-negotiated capped call transactions with certain financial institutions. The Company used part of the proceeds from the issuance of the 2029 Notes to repurchase $230.0 million aggregate principal amount of the 2025 Notes in privately-negotiated transactions for an aggregate cash repurchase consideration of $270.5 million. Contemporaneously with the 2025 Notes Repurchase Transaction, the Company and the financial institutions party to the 2025 Capped Calls agreed to terminate a portion of the 2025 Capped Calls in a notional amount corresponding to the amount of 2025 Notes repurchased.
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedMD&A
Due to the global nature of LivaNova’s operations, the Company is exposed to FX fluctuations. Historically, LivaNova has maintained a foreign currency exchange rate risk management strategy that utilizes cash flow hedges and freestanding foreign currency derivatives to reduce the Company’s exposure to unanticipated fluctuations in forecasted revenue and costs, inter-company debt, bank deposits, accounts receivable, and accounts payable caused by changes in foreign currency exchange rates. Upon the settlement of LivaNova’s foreign currency cash flow hedges in the fourth quarter of 2022 and following an in-depth analysis of the utility of the Company’s cash flow hedging program, LivaNova discontinued its foreign currency cash flow hedging program. LivaNova continues to use freestanding derivative forward contracts to offset exposure to the variability of the value associated with assets and liabilities denominated in a foreign currency.
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedMD&A
LivaNova is subject to interest rate risk on its investments and debt. Historically, LivaNova has entered into interest rate derivative instruments designated as cash flow hedges to manage the exposure to interest rate movements and to reduce the risk of increased borrowing costs by converting floating-rate debt into fixed-rate debt. Under these agreements, LivaNova agrees to
Read it in 10-K Feb 25, 2025 at sec.gov
RemovedMD&A
exchange, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to agreed-upon notional principal amounts. These interest rate swaps are structured to mirror the payment terms of the underlying loan. The Company’s outstanding interest rate swaps expired on April 6, 2023. LivaNova elected not to renew the interest rate swaps. Interest expense associated with the Initial Term Facility is principally offset by holding proceeds from the Term Facilities in a depository account, which earns a floating rate of interest.
Read it in 10-K Feb 25, 2025 at sec.gov
RewordedMD&A
Cash used in investing activities during for the year ended December 31, 2024 2025 increased $7.8 $24.8 million, compared to the prior year, primarily due to an increase in purchases of property, plant, and equipment of $12.1 million primarily $33.9 million, principally related to purchases and development of internal-use software, partially offset by a decrease proceeds of $6.5 million from the sale of LivaNova’s investment in purchases Ceribell, Inc. and proceeds of equity investments $7.2 million primarily from the sale of $5.4 million. land to support manufacturing capacity expansion in other locations.
Read it in 10-K Feb 25, 2026 at sec.gov
RewordedMD&A
The increase in segment income was primarily due to an increase in net revenue, as described above, as well as a net decrease in R&D expense, expense primarily resulting from an $18.9 million reduction in costs associated with the winding down Company’s DTD program, partially offset by an $11.2 million increase in R&D expense associated with the development of the Company’s heart failure program of $24.8 million. LivaNova’s aura6000 System for treating OSA.
Read it in 10-K Feb 25, 2026 at sec.gov
RewordedMD&A
Compared with the year ended December 31, 2023, 2024, the change in the effective tax rate for 2024 2025 was primarily attributable to year-over-year changes in income before income tax in countries with varying statutory tax rates, certain discrete tax items, including the mix of taxable income in various jurisdictions, non-deductible interest and premiums, SNIA environmental liability, and changes in tax valuation allowances.
Read it in 10-K Feb 25, 2026 at sec.gov
RewordedMD&A
LivaNova has filed claims for insurance reimbursement of covered direct costs and business interruption losses related to this incident and has submitted additional claims and supplemental requests for and, as of December 31, 2025, the reimbursement as new costs have been incurred. process is substantially complete.
Read it in 10-K Feb 25, 2026 at sec.gov
RewordedMD&A
During For the years ended December 31, 2025 and 2024, LivaNova received $8.4 million, including $5.1 $0.6 million in reimbursement of covered costs and $3.3 million million, respectively, in reimbursement of business interruption losses under the Company’s cyber insurance policy. losses.
Read it in 10-K Feb 25, 2026 at sec.gov
RewordedMD&A
The Company designs, develops, manufactures, markets, and sells products products, therapies, and therapies services that are consistent with LivaNova’s mission to provide hope for patients and their families through “create ingenious medical technologies, delivering life-changing solutions in select neurological and cardiac conditions. that ignite patient turnarounds.
Read it in 10-K Feb 25, 2026 at sec.gov
RewordedMD&A
During 2024, Through December 31, 2025, LivaNova has received $8.4 million, $10.7 million of insurance reimbursements, including $5.1 $6.8 million in reimbursement of covered direct costs and $3.3 $3.9 million in reimbursement of business interruption losses under the Company’s cyber insurance policy. losses.
Read it in 10-K Feb 25, 2026 at sec.gov
RewordedMD&A
The decrease increase was primarily due to unfavorable product mix, partially offset by a decrease in cost of sales and marketing expenses driven by from the winding down of the ACS segment, as described above, as well as favorable volume leverage. segment.
Read it in 10-K Feb 25, 2026 at sec.gov
RewordedMD&A
LivaNova incurred interest expense of $49.3 million for the year ended December 31, 2025, compared to $63.1 million for the year ended December 31, 2024, compared to $58.9 million for the year ended December 31, 2023. 2024.
Read it in 10-K Feb 25, 2026 at sec.gov
RewordedMD&A
LivaNova is exposed to certain market risks as part of its ongoing business operations, including risks from foreign currency exchange and interest rates, interest rate risks, and concentration of procurement suppliers as well as credit risk, that could adversely affect LivaNova’s consolidated financial position, results of operations, or cash flows. flows, and financial position.
Read it in 10-K Feb 25, 2026 at sec.gov
RewordedMD&A
Cardiopulmonary Neuromodulation net revenue for the year ended December 31, 2024 2025 increased 13.1% 7.0% to $683.5 $592.8 million compared to the year ended December 31, 2023, 2024, with growth across all regions, driven by strong consumables demand and Essenz Perfusion System sales. regions.
Read it in 10-K Feb 25, 2026 at sec.gov
RewordedMD&A
The decrease was primarily due to a decrease in the amount recorded for the litigation provision related to LivaNova’s 3T Heater-Cooler device of $14.8 million and $15.3 million, as well as a decrease in the amount recorded for the Saluggia site decommissioning provision restructuring expense of $2.3 $13.5 million.
Read it in 10-K Feb 25, 2026 at sec.gov

Sources

The two latest 10-Ks on EDGAR, section by section. Each change links to the text at sec.gov.

Also

New risk factors: paragraphs with nothing like them last year, quoted in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/LIVN/export.csv") into a cell.

Next:Related parties
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.